Alumis Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Alumis Inc (ALMS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Alumis Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 7M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-10.1% annualized vs trailing 12 months).
- Scale: Alumis Inc ranks #158 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Alumis Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Structure: Alumis Inc operates in the following segments: Single reportable segment; and reports the following subsidiaries: Acelyrin Inc (competes with Jasper Therapeutics Inc , Moonlake Immunotherapeutics, Viridian Therapeutics Inc ).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ALMS Sales vs. its Competitors, Q2 2026
Alumis Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -37.7% for Alumis Inc. Alumis Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Alumis Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Alumis inc | - | - | - | Yes |
| High-Confidence Competitors (3) | - | |||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ALMS Stock Performance relative to its Competitors
ALMS Stock Performance relative to High-Confidence Competitors
ALMS Stock Performance relative to Similar-Size Competitors
Alumis Inc's Competitors Named by the Company
Competitive relationships identified from Alumis Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Viridian Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
Company report basis, confidence, active dates and source counts for Alumis Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Alumis Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Alumis inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).